S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
OTCMKTS:PBIO

Pressure BioSciences (PBIO) Competitors

$0.85
-0.02 (-2.31%)
(As of 05:39 PM ET)
Compare
Today's Range
$0.80
$0.88
50-Day Range
$0.84
$1.50
52-Week Range
$0.79
$2.20
Volume
38,468 shs
Average Volume
28,157 shs
Market Capitalization
$14.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

PBIO vs. PRPO, TLIS, SQL, RPID, BLI, AEZS, NSPR, CLRB, PCHM, and UPC

Should you be buying Pressure BioSciences stock or one of its competitors? The main competitors of Pressure BioSciences include Precipio (PRPO), Talis Biomedical (TLIS), SeqLL (SQL), Rapid Micro Biosystems (RPID), Berkeley Lights (BLI), Aeterna Zentaris (AEZS), InspireMD (NSPR), Cellectar Biosciences (CLRB), PharmChem (PCHM), and Universe Pharmaceuticals (UPC). These companies are all part of the "medical" sector.

Pressure BioSciences vs.

Pressure BioSciences (OTCMKTS:PBIO) and Precipio (NASDAQ:PRPO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, community ranking, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

Precipio has a net margin of -108.80% compared to Pressure BioSciences' net margin of -939.40%. Pressure BioSciences' return on equity of 0.00% beat Precipio's return on equity.

Company Net Margins Return on Equity Return on Assets
Pressure BioSciences -939.40% N/A -751.44%
Precipio -108.80% -61.29% -47.03%

Precipio received 190 more outperform votes than Pressure BioSciences when rated by MarketBeat users. Likewise, 73.51% of users gave Precipio an outperform vote while only 61.65% of users gave Pressure BioSciences an outperform vote.

CompanyUnderperformOutperform
Pressure BioSciencesOutperform Votes
82
61.65%
Underperform Votes
51
38.35%
PrecipioOutperform Votes
272
73.51%
Underperform Votes
98
26.49%

Precipio has higher revenue and earnings than Pressure BioSciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pressure BioSciences$1.73 million8.37-$16.08 million-$1.59-0.53
Precipio$9.41 million1.52-$12.20 millionN/AN/A

Pressure BioSciences has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, Precipio has a beta of 2.21, indicating that its stock price is 121% more volatile than the S&P 500.

In the previous week, Precipio had 1 more articles in the media than Pressure BioSciences. MarketBeat recorded 2 mentions for Precipio and 1 mentions for Pressure BioSciences. Precipio's average media sentiment score of 0.44 beat Pressure BioSciences' score of -0.75 indicating that Precipio is being referred to more favorably in the news media.

Company Overall Sentiment
Pressure BioSciences Negative
Precipio Neutral

0.1% of Pressure BioSciences shares are owned by institutional investors. Comparatively, 9.6% of Precipio shares are owned by institutional investors. 14.6% of Pressure BioSciences shares are owned by company insiders. Comparatively, 10.6% of Precipio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Precipio has a consensus target price of $2.85, indicating a potential upside of 367.98%. Given Precipio's higher possible upside, analysts clearly believe Precipio is more favorable than Pressure BioSciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pressure BioSciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Precipio
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Summary

Precipio beats Pressure BioSciences on 11 of the 14 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of OTCMKTS and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PBIO vs. The Competition

MetricPressure BioSciencesAnalytical instruments IndustryMedical SectorOTCMKTS Exchange
Market Cap$14.47M$5.65B$4.47B$7.54B
Dividend YieldN/A0.42%2.41%18.43%
P/E Ratio-0.537.3693.408.36
Price / Sales8.3711.713,613.37132.19
Price / CashN/A74.3522.2319.29
Price / Book-0.3342.394.504.02
Net Income-$16.08M-$271.20M$117.01M$711.17M
7 Day Performance-3.42%-3.56%-2.94%-1.26%
1 Month Performance-5.66%-2.72%0.45%-1.14%
1 Year Performance-50.87%-23.34%18.35%-2.49%

Pressure BioSciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PRPO
Precipio
1.444 of 5 stars
$0.65
flat
$2.85
+341.9%
-44.4%$15.12M$9.41M0.0054Gap Down
TLIS
Talis Biomedical
2.1436 of 5 stars
$0.47
+2.2%
N/A-49.0%$12.59M$4.81M-0.13242Short Interest ↓
Positive News
Gap Down
SQL
SeqLL
0 of 5 stars
$0.56
+39.9%
N/A-26.5%$7.79M$80,000.00-1.447News Coverage
Gap Up
High Trading Volume
RPID
Rapid Micro Biosystems
2.5784 of 5 stars
$1.13
+10.8%
$2.75
+143.4%
-80.2%$47.82M$17.13M-0.81202Positive News
BLI
Berkeley Lights
2.0807 of 5 stars
$0.81
-6.9%
$6.50
+702.5%
-85.8%$58.46M$78.60M-0.57293
AEZS
Aeterna Zentaris
1.428 of 5 stars
$3.04
+1.7%
N/A-45.3%$14.79M$5.64M-0.6111Analyst Report
Short Interest ↓
NSPR
InspireMD
0 of 5 stars
$1.77
-6.8%
$4.75
+168.4%
-24.8%$14.74M$5.17M-0.77N/A
CLRB
Cellectar Biosciences
2.2292 of 5 stars
$1.53
+5.5%
$7.00
+357.5%
-65.2%$14.90MN/A-0.4012Short Interest ↓
Gap Up
PCHM
PharmChem
0 of 5 stars
$2.91
+1.0%
N/AN/A$14.73MN/A0.00170
UPC
Universe Pharmaceuticals
0 of 5 stars
$0.68
+11.6%
N/A-34.8%$14.68M$40.14M0.00N/AGap Up

Related Companies and Tools

This page (OTCMKTS:PBIO) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -